{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T09:00:33Z","timestamp":1769245233083,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020097","name":"Foundation for Opioid Response Efforts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.japh.2024.102308","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T17:43:21Z","timestamp":1733334201000},"page":"102308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Barriers to and facilitators of buprenorphine dispensing for opioid use disorder: Evidence from focus groups in Appalachian Kentucky"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6153-831X","authenticated-orcid":false,"given":"Douglas R.","family":"Oyler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7612-1587","authenticated-orcid":false,"given":"Dustin K.","family":"Miracle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3438-7233","authenticated-orcid":false,"given":"Hannah","family":"Hesener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0115-9147","authenticated-orcid":false,"given":"Laura","family":"Stinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3462-0920","authenticated-orcid":false,"given":"Monica","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2492-1592","authenticated-orcid":false,"given":"Adrienne","family":"Matson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4749-6563","authenticated-orcid":false,"given":"Patricia R.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.japh.2024.102308_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.japh.2024.102308_bib2","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.japh.2022.07.003","article-title":"Access to community pharmacies: a nationwide geographic information systems cross-sectional analysis","volume":"62","author":"Berenbrok","year":"2022","journal-title":"J Am Pharmaceut Assoc"},{"key":"10.1016\/j.japh.2024.102308_bib3","series-title":"The pharmacy access to resources and medications for opioid use disorder (PhARM-OUD) guideline: a joint consensus practice guideline from the Natinoal Association of Boards of Pharmacy and the National Community Pharmacists Association [draft]","author":"Committee","year":"2024"},{"key":"10.1016\/j.japh.2024.102308_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109518","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states","volume":"237","author":"Hill","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2024.102308_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108729","article-title":"Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden","volume":"224","author":"Kazerouni","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2024.102308_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.drugpo.2018.04.011","article-title":"Opioid-related mortality in rural America: geographic heterogeneity and intervention strategies","volume":"57","author":"Rigg","year":"2018","journal-title":"Int J Drug Policy"},{"issue":"26","key":"10.1016\/j.japh.2024.102308_bib8","first-page":"563","article-title":"Vital signs: variation among states in prescribing of opioid pain relievers and benzodiazepines - United States, 2012","volume":"63","author":"Paulozzi","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"10.1016\/j.japh.2024.102308_bib9","first-page":"988","article-title":"Geographic variation in opioid prescribing in the U.S","volume":"13","author":"McDonald","year":"2012","journal-title":"J\u00a0Pain"},{"key":"10.1016\/j.japh.2024.102308_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102701","article-title":"Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky","volume":"85","author":"Cooper","year":"2020","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.japh.2024.102308_bib11","article-title":"Rural community pharmacist willingness to dispense Suboxone(R) - a secret shopper investigation in south-central Appalachia","volume":"4","author":"Trull","year":"2021","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"1","key":"10.1016\/j.japh.2024.102308_bib12","first-page":"252","article-title":"Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: a national survey of community-based pharmacists","volume":"63","author":"Hill","year":"2023","journal-title":"J\u00a0Am Pharmaceut Assoc"},{"issue":"5","key":"10.1016\/j.japh.2024.102308_bib13","first-page":"1558","article-title":"Independent community pharmacists' attitudes and intentions toward dispensing buprenorphine\/naloxone for opioid use disorder","volume":"63","author":"Zalmai","year":"2023","journal-title":"J\u00a0Am Pharmaceut Assoc"},{"issue":"2S","key":"10.1016\/j.japh.2024.102308_bib14","first-page":"S12","article-title":"Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia","volume":"57","author":"Thornton","year":"2017","journal-title":"J\u00a0Am Pharmaceut Assoc"},{"issue":"7","key":"10.1016\/j.japh.2024.102308_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5055\/jom.2021.0645","article-title":"Patient satisfaction with clinic-based medication pick up: addressing pharmacy-level challenges to buprenorphine access","volume":"17","author":"Kolb","year":"2021","journal-title":"J\u00a0Opioid Manag"},{"issue":"8","key":"10.1016\/j.japh.2024.102308_bib17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1056\/NEJMp2002908","article-title":"When prescribing isn't enough - pharmacy-level barriers to buprenorphine access","volume":"383","author":"Cooper","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.japh.2024.102308_bib18","first-page":"1606","article-title":"North Carolina community pharmacists' buprenorphine dispensing practices and attitudes","volume":"62","author":"Carpenter","year":"2022","journal-title":"J\u00a0Am Pharmaceut Assoc"},{"issue":"5","key":"10.1016\/j.japh.2024.102308_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.1077","article-title":"Barriers to buprenorphine dispensing by Medicaid-participating community retail pharmacies","volume":"5","author":"Freeman","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"2","key":"10.1016\/j.japh.2024.102308_bib20","first-page":"588","article-title":"Ensuring buprenorphine access in rural community pharmacies to prevent overdoses","volume":"62","author":"Ostrach","year":"2022","journal-title":"J\u00a0Am Pharmaceut Assoc"},{"key":"10.1016\/j.japh.2024.102308_bib21","article-title":"Factors in rural community buprenorphine dispensing","volume":"9","author":"Major","year":"2023","journal-title":"Explor Res Clin Soc Pharm"},{"key":"10.1016\/j.japh.2024.102308_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109710","article-title":"The prevalence of opioid use disorder in Kentucky's counties: a two-year multi-sample capture-recapture analysis","volume":"242","author":"Thompson","year":"2023","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.japh.2024.102308_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4997\/jrcpe.2015.305","article-title":"Qualitative research in healthcare: an introduction to grounded theory using thematic analysis","volume":"45","author":"Chapman","year":"2015","journal-title":"J\u00a0R Coll Physicians Edinb"},{"key":"10.1016\/j.japh.2024.102308_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/2050312118822927","article-title":"Grounded theory research: a design framework for novice researchers","volume":"7","author":"Chun Tie","year":"2019","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.japh.2024.102308_bib27","article-title":"Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use","volume":"5","author":"Winstanley","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"issue":"6","key":"10.1016\/j.japh.2024.102308_bib28","first-page":"e173","article-title":"Community pharmacist engagement in opioid use disorder prevention and treatment behaviors: a descriptive analysis","volume":"60","author":"Salwan","year":"2020","journal-title":"J\u00a0Am Pharmaceut Assoc"},{"issue":"7","key":"10.1016\/j.japh.2024.102308_bib30","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/add.15353","article-title":"Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the national drug abuse treatment clinical trials network","volume":"116","author":"Wu","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.japh.2024.102308_bib31","series-title":"The pharmacy access to resources and medication for opioid use disorder (PhARM- OUD) guideline","author":"Varisco","year":"2024"},{"issue":"2","key":"10.1016\/j.japh.2024.102308_bib33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/29767342231215178","article-title":"Relationships between stigma, risk tolerance, and buprenorphine dispensing intentions among community-based pharmacists: results from a national sample","volume":"45","author":"Light","year":"2024","journal-title":"Subst Use Addctn J"},{"issue":"2S Suppl 1","key":"10.1016\/j.japh.2024.102308_bib34","first-page":"1","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","year":"2020","journal-title":"J\u00a0Addict Med"},{"issue":"9","key":"10.1016\/j.japh.2024.102308_bib35","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatr"},{"issue":"12","key":"10.1016\/j.japh.2024.102308_bib36","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial","volume":"174","author":"Fiellin","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1016\/j.japh.2024.102308_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.34168","article-title":"Prescribing characteristics associated with opioid overdose following buprenorphine taper","volume":"5","author":"Bozinoff","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"13","key":"10.1016\/j.japh.2024.102308_bib38","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.japh.2024.102308_bib39","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jamapsychiatry.2013.2216","article-title":"A\u00a0randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers","volume":"70","author":"Sigmon","year":"2013","journal-title":"JAMA Psychiatr"},{"issue":"2","key":"10.1016\/j.japh.2024.102308_bib40","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1360-0443.2008.02455.x","article-title":"Buprenorphine tapering schedule and illicit opioid use","volume":"104","author":"Ling","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.japh.2024.102308_bib41","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.drugalcdep.2018.05.010","article-title":"Tapering off and returning to buprenorphine maintenance in a primary care office based addiction treatment (OBAT) program","volume":"189","author":"Weinstein","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.japh.2024.102308_bib42","first-page":"68","article-title":"A\u00a0brief online training to address pharmacists' willingness to dispense buprenorphine","volume":"18","author":"Carpenter","year":"2024","journal-title":"J\u00a0Addict Med"},{"issue":"5","key":"10.1016\/j.japh.2024.102308_bib43","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.16089","article-title":"Pharmacy availability of buprenorphine for opioid use disorder treatment in the US","volume":"6","author":"Weiner","year":"2023","journal-title":"JAMA Netw Open"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431912400339X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431912400339X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T04:47:55Z","timestamp":1742014075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154431912400339X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S154431912400339X"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2024.102308","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers to and facilitators of buprenorphine dispensing for opioid use disorder: Evidence from focus groups in Appalachian Kentucky","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2024.102308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102308"}}